TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

被引：0
|
作者：
Choueiri, Toni K.
Albiges, Laurence
Mckay, Rana R.
Pal, Sumanta K.
Hammers, Hans J.
Heng, Daniel Yick Chin
Beckermann, Katy
Kasturi, Vijay
Motzer, Robert J.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Gustave Roussy, Villejuif, France
[3] Univ Calif San Diego Hlth, La Jolla, CA USA
[4] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA
[5] UT SouthWestern Kidney Canc Program, Dallas, TX USA
[6] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[8] AVEO Oncol, Boston, MA USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4605
引用
收藏
页数：1
相关论文
共 9 条
  • [1] TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.
    Choueiri, Toni K.
    Albiges, Laurence
    Hammers, Hans J.
    Mckay, Rana R.
    Heng, Daniel Yick Chin
    Beckermann, Katy
    Kasturi, Vijay
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3TiNivo-2 Study
    Choueiri, Toni K.
    Albiges, Laurence
    Barthelemy, Philippe
    Iacovelli, Roberto
    Emambux, Sheik
    Molina-Cerrillo, Javier
    Garmezy, Benjamin
    Barata, Pedro
    Basu, Arnab
    Bourlon, Maria
    Moon, Helen
    Ratta, Raffaele
    McKay, Rana R.
    Chehrazi-Raffle, Alexander
    Hammers, Hans
    Heng, Daniel Y. C.
    Braendle, Edgar
    Beckermann, Kathryn E.
    McGregor, Bradley A.
    Motzer, Robert J.
    LANCET, 2024, 404 (10460):
  • [3] TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
    Rini, Brian I.
    Pal, Sumanta K.
    Escudier, Bernard
    Atkins, Michael B.
    Hutson, Thomas E.
    Porta, Camillo
    Verzoni, Elena
    Needle, Michael N.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Patient-reported outcomes (PROs) for tivozanib (TIVO) plus nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.
    Beckermann, Katy
    Choueiri, Toni K.
    Motzer, Robert J.
    Barthelemy, Philippe
    Iacovelli, Roberto
    Emambux, Sheik
    Molina-Cerrillo, Javier
    Garmezy, Benjamin
    Barata, Pedro C.
    Mckay, Rana R.
    Chehrazi-Raffle, Alex
    Hammers, Hans J.
    Heng, Daniel Yick Chin
    Braendle, Edgar E.
    Lebedinsky, Claudia
    Jin, Bo
    Albiges, Laurence
    Mcgregor, Bradley Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [5] TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).
    Pal, Sumanta K.
    Escudier, Bernard
    Atkins, Michael B.
    Hutson, Thomas E.
    Porta, Camillo
    Verzoni, Elena
    Needle, Michael N.
    McDermott, David F.
    Rini, Brian, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
    Rini, Brian I.
    Atkins, Michael B.
    Escudier, Bernard J.
    Hutson, Thomas E.
    Koralewski, Piotr
    McDermott, David F.
    Pal, Sumanta K.
    Needle, Michael N.
    Porta, Camillo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.
    Pal, Sumanta K.
    Albiges, Laurence
    Rodriguez, Cristina Suarez
    Liu, Bo
    Doss, Jennifer
    Khurana, Sudha
    Scheffold, Christian
    Voss, Martin H.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)
    Qin, Shukui
    Lin, Xiaoyan
    Meng, Zhiqaing
    Ren, Zhenggang
    Bai, Yuxian
    Gu, Shanzhi
    Zheng, Li
    Li, Qiu
    Oh, Sun-Yong
    Guo, Yabing
    Kang, Yoong-Koo
    Kao, Wei-Yu
    Li, Wei
    Yoon, Jung-Hwan
    Zhang, Helong
    Chen, Pei-Jer
    Yang, Tsai-Sheng
    Heo, Jeong
    Zheng, Zhendong
    Xie, Hui
    Yu, Zhinuan
    CANCER RESEARCH, 2023, 83 (08)
  • [9] Erstlinientherapie beim nichtresektablen/metastasierten nichtklarzelligen NierenzellkarzinomRandomisierte Phase-II-Open-label-Studie mit Nivolumab in Kombination mit Ipilimumab versus Sunitinibmonotherapie bei Patienten mit zuvor unbehandeltem fortgeschrittenen (inoperablen oder metastasierenden) nichtklarzelligen Nierenzellkarzinom – SUNNIFORECASTFirst-line therapy for non-resectable metastatic non-clear cell renal cell carcinomaA Phase 2, Randomized, open-label Study of Nivolumab Combined with Ipilimumab versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma – SUNNIFORECAST
    H. Rexer
    T. Steiner
    L. Bergmann
    Forum, 2019, 34 (6) : 565 - 567
1